684 related articles for article (PubMed ID: 21555567)
1. Selective killing of K-ras mutant cancer cells by small molecule inducers of oxidative stress.
Shaw AT; Winslow MM; Magendantz M; Ouyang C; Dowdle J; Subramanian A; Lewis TA; Maglathin RL; Tolliday N; Jacks T
Proc Natl Acad Sci U S A; 2011 May; 108(21):8773-8. PubMed ID: 21555567
[TBL] [Abstract][Full Text] [Related]
2. Synthetic lethal screening identifies compounds activating iron-dependent, nonapoptotic cell death in oncogenic-RAS-harboring cancer cells.
Yang WS; Stockwell BR
Chem Biol; 2008 Mar; 15(3):234-45. PubMed ID: 18355723
[TBL] [Abstract][Full Text] [Related]
3. Mouse tissues that undergo neoplastic progression after K-Ras activation are distinguished by nuclear translocation of phospho-Erk1/2 and robust tumor suppressor responses.
Parikh N; Shuck RL; Nguyen TA; Herron A; Donehower LA
Mol Cancer Res; 2012 Jun; 10(6):845-55. PubMed ID: 22532587
[TBL] [Abstract][Full Text] [Related]
4. Killing of Kras-mutant colon cancer cells via Rac-independent actin remodeling by the βGBP cytokine, a physiological PI3K inhibitor therapeutically effective in vivo.
Mallucci L; Shi DY; Davies D; Jordan P; Nicol A; Lotti L; Mariani-Costantini R; Verginelli F; Wells V; Zicha D
Mol Cancer Ther; 2012 Sep; 11(9):1884-93. PubMed ID: 22752425
[TBL] [Abstract][Full Text] [Related]
5. Suppression of PKC causes oncogenic stress for triggering apoptosis in cancer cells.
Ganapathy S; Peng B; Shen L; Yu T; Lafontant J; Li P; Xiong R; Makriyannis A; Chen C
Oncotarget; 2017 May; 8(19):30992-31002. PubMed ID: 28415683
[TBL] [Abstract][Full Text] [Related]
6. Ferroptosis, a novel pharmacological mechanism of anti-cancer drugs.
Su Y; Zhao B; Zhou L; Zhang Z; Shen Y; Lv H; AlQudsy LHH; Shang P
Cancer Lett; 2020 Jul; 483():127-136. PubMed ID: 32067993
[TBL] [Abstract][Full Text] [Related]
7. Group IIa secretory phospholipase expression correlates with group IIa secretory phospholipase inhibition-mediated cell death in K-ras mutant lung cancer cells.
Yu JA; Li H; Meng X; Fullerton DA; Nemenoff RA; Mitchell JD; Weyant MJ
J Thorac Cardiovasc Surg; 2012 Dec; 144(6):1479-85. PubMed ID: 23026567
[TBL] [Abstract][Full Text] [Related]
8. Temporal dissection of K-ras(G12D) mutant in vitro and in vivo using a regulatable K-ras(G12D) mouse allele.
Wang Z; Feng Y; Bardeesy N; Wong KK; Liu XY; Ji H
PLoS One; 2012; 7(5):e37308. PubMed ID: 22606359
[TBL] [Abstract][Full Text] [Related]
9. Protein kinase C δ is a downstream effector of oncogenic K-ras in lung tumors.
Symonds JM; Ohm AM; Carter CJ; Heasley LE; Boyle TA; Franklin WA; Reyland ME
Cancer Res; 2011 Mar; 71(6):2087-97. PubMed ID: 21335545
[TBL] [Abstract][Full Text] [Related]
10. Novel synthetic oleanane triterpenoid AMR-MeOAc inhibits K-Ras through ERK, Akt and survivin in pancreatic cancer cells.
Rabi T; Venkatanarashiman M
Phytomedicine; 2014 Mar; 21(4):491-6. PubMed ID: 24215674
[TBL] [Abstract][Full Text] [Related]
11. A new ferrocene derivative blocks K-Ras localization and function by oxidative modification at His95.
Rehl KM; Selvakumar J; Pitsch RL; Hoang D; Arumugam K; Harshman SW; Gorfe AA; Cho KJ
Life Sci Alliance; 2023 Nov; 6(11):. PubMed ID: 37666666
[TBL] [Abstract][Full Text] [Related]
12. Identification of a small molecule with synthetic lethality for K-ras and protein kinase C iota.
Guo W; Wu S; Liu J; Fang B
Cancer Res; 2008 Sep; 68(18):7403-8. PubMed ID: 18794128
[TBL] [Abstract][Full Text] [Related]
13. Prx I suppresses K-ras-driven lung tumorigenesis by opposing redox-sensitive ERK/cyclin D1 pathway.
Park YH; Kim SU; Lee BK; Kim HS; Song IS; Shin HJ; Han YH; Chang KT; Kim JM; Lee DS; Kim YH; Choi CM; Kim BY; Yu DY
Antioxid Redox Signal; 2013 Aug; 19(5):482-96. PubMed ID: 23186333
[TBL] [Abstract][Full Text] [Related]
14. Synthetic Lethality of a Novel Small Molecule Against Mutant KRAS-Expressing Cancer Cells Involves AKT-Dependent ROS Production.
Iskandar K; Rezlan M; Yadav SK; Foo CH; Sethi G; Qiang Y; Bellot GL; Pervaiz S
Antioxid Redox Signal; 2016 May; 24(14):781-94. PubMed ID: 26714745
[TBL] [Abstract][Full Text] [Related]
15. Antitumor effect of novel small chemical inhibitors of Snail-p53 binding in K-Ras-mutated cancer cells.
Lee SH; Shen GN; Jung YS; Lee SJ; Chung JY; Kim HS; Xu Y; Choi Y; Lee JW; Ha NC; Song GY; Park BJ
Oncogene; 2010 Aug; 29(32):4576-87. PubMed ID: 20531295
[TBL] [Abstract][Full Text] [Related]
16. Targeting the RAS-dependent chemoresistance: The Warburg connection.
Serna-Blasco R; Sanz-Álvarez M; Aguilera Ó; García-Foncillas J
Semin Cancer Biol; 2019 Feb; 54():80-90. PubMed ID: 29432815
[TBL] [Abstract][Full Text] [Related]
17. Recent Advances in Developing K-Ras Plasma Membrane Localization Inhibitors.
Ye N; Xu Q; Li W; Wang P; Zhou J
Curr Top Med Chem; 2019; 19(23):2114-2127. PubMed ID: 31475899
[TBL] [Abstract][Full Text] [Related]
18. Reactive oxygen species-mediated synergistic and preferential induction of cell death and reduction of clonogenic resistance in breast cancer cells by combined cisplatin and FK228.
Pluchino LA; Choudhary S; Wang HC
Cancer Lett; 2016 Oct; 381(1):124-32. PubMed ID: 27477899
[TBL] [Abstract][Full Text] [Related]
19. Exploiting cancer cell vulnerabilities to develop a combination therapy for ras-driven tumors.
De Raedt T; Walton Z; Yecies JL; Li D; Chen Y; Malone CF; Maertens O; Jeong SM; Bronson RT; Lebleu V; Kalluri R; Normant E; Haigis MC; Manning BD; Wong KK; Macleod KF; Cichowski K
Cancer Cell; 2011 Sep; 20(3):400-13. PubMed ID: 21907929
[TBL] [Abstract][Full Text] [Related]
20. An oxanthroquinone derivative that disrupts RAS plasma membrane localization inhibits cancer cell growth.
Tan L; Cho KJ; Neupane P; Capon RJ; Hancock JF
J Biol Chem; 2018 Aug; 293(35):13696-13706. PubMed ID: 29970615
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
